Cardiac arrest & resuscitation
Serum biomarkers of postanoxic encephalopathy in relation to ghrelin treatment. A secondary analysis of the Ghrelin in Coma (GRECO) trial
Authors' conclusion
Acyl-ghrelin treatment during the first week after cardiac arrest was associated with less GFAP elevation in the first three days, suggesting reduced astroglial activation and/or damage.
Study context
- Population
- Comatose patients after cardiac arrestof 160 trial participants
- Participants
- 125 patients
- Comparison
- IV acyl-ghrelin 600 µg vs placebo, twice daily for 7 days
- Acyl-ghrelinn = 65
- Primary endpoint
- Circulating neuro-biomarkers (neuron-specific enolase (NSE), UCH-L1, S100, GFAP, neurofilament light (NfL), pTau181) on days 0, 1, 3 and 7
Methodological detailsphase 2, double-blind, placebo-controlled
- Phase 2
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Treatment-interaction effect on serum GFAP (linear mixed-effect models) · days 1 and 3
Glial fibrillary acidic protein (GFAP) treatment-interaction estimate, day 1 (p = 0.015)
0.855
GFAP treatment-interaction estimate, day 3 (p = 0.0037)
1.017
Further findings
Other neuro-biomarkers and timepoints
- No significant effect of acyl-ghrelin on other timepoints, except on day 0 for S100, pTau181 and ubiquitin carboxyl hydrolase L1 (UCH-L1)
Original publication
Serum biomarkers of postanoxic encephalopathy in relation to ghrelin treatment. A secondary analysis of the GRECO trial. Resuscitation. Published 20 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →